PD-L1
细胞生物学
免疫检查点
免疫系统
癌症研究
细胞内
生物
化学
T细胞
免疫疗法
免疫学
作者
Qiang Zhu,Hongxing Wang,Siyuan Chai,Liang Xu,Bingyi Lin,Wen Yi,Liming Wu
标识
DOI:10.1073/pnas.2216796120
摘要
Programmed-death ligand 1 (PD-L1) and its receptor programmed cell death 1 (PD-1) mediate T cell–dependent immunity against tumors. The abundance of cell surface PD-L1 is a key determinant of the efficacy of immune checkpoint blockade therapy targeting PD-L1. However, the regulation of cell surface PD-L1 is still poorly understood. Here, we show that lysosomal degradation of PD-L1 is regulated by O -linked N -acetylglucosamine ( O -GlcNAc) during the intracellular trafficking pathway. O -GlcNAc modifies the hepatocyte growth factor-regulated tyrosine kinase substrate (HGS), a key component of the endosomal sorting machinery, and subsequently inhibits its interaction with intracellular PD-L1, leading to impaired lysosomal degradation of PD-L1. O -GlcNAc inhibition activates T cell–mediated antitumor immunity in vitro and in immune-competent mice in a manner dependent on HGS glycosylation. Combination of O -GlcNAc inhibition with PD-L1 antibody synergistically promotes antitumor immune response. We also designed a competitive peptide inhibitor of HGS glycosylation that decreases PD-L1 expression and enhances T cell–mediated immunity against tumor cells. Collectively, our study reveals a link between O -GlcNAc and tumor immune evasion, and suggests strategies for improving PD-L1-mediated immune checkpoint blockade therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI